Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Issue 2 (December 2015) - Kelly, Ronan; Chung, Ki; Gu, Yu; Steele, Keith; Rebelatto, Marlon; Robbins, Paul; Tavakkoli, Fatemeh; Karakunnel, Joyson; Lai, Dominic; Almhanna, Khaldoun